Living Evidence for Diabetes
Diabetes is an National Health Priority area that affects approx. 1.7 million Australians and represents an estimated $15 billion per annum in direct and indirect costs to the Australian economy.
The Living Evidence for Diabetes Consortium is a collaboration between the Australian Diabetes Society (ADS), Diabetes Australia (DA), the Australian Diabetes Educators Association (ADEA) and the Australia and New Zealand Society for Paediatric Endocrinology and Diabetes (ANZSPED), with representation from the Royal Australian College of General Practitioners (RACGP) and Cochrane Australia.
The Consortium has developed evidence based clinical guidelines for diabetes containing selected recommendations regarding:
Medical device technology for the management of Type 1 Diabetes; and
Medications for blood glucose management in adults with Type 2 Diabetes.
The clinical guidelines for diabetes were approved by the NHMRC in 2020. These guidelines are living and as such, the LED team are regularly monitoring research to update recommendations at regular intervals or as new evidence accumulates.
In 2022, the consortium expanded its scope and selected ‘In hospital management of glycaemia’ as the next clinical topic for which to develop living recommendations. The Guideline Development group selected 5 clinical questions and the evidence based recommendations have just been approved by the NHMRC. The clinical questions considered intensive versus less intensive blood glucose targets, the use of combination basal plus bolus insulin, specialist inpatient diabetes teams and optimal solutions for the resolution of diabetic ketoacidosis.
The guidelines are accessible through MAGICapp.
Find out more in the latest LED newsletter and add your details below to join the LED mailing list for news and new and updated recommendations.
For more information about this project please contact Heath White heath.white@monash.edu